Introduction
Non-small cell lung cancer (NSCLC) is still the leading cause of cancer-related deaths worldwide. The prognosis is poor for most patients with NSCLC, even with the most current treatment regimens, which include surgery, chemotherapy, and radiation. Targeted molecular therapy is effective for advanced NSCLC patients with associated gene mutations. Although driver genes, including epidermal growth factor receptor (EGFR) and Kirsten rat sarcoma viral oncogene (KRAS), are common molecules in lung adenocarcinomas, the c-ros oncogene 1 receptor tyrosine kinase (ROS1) rearrangement has been identified in only 1%-2% of NSCLC cases. 1, 2 Previous studies have suggested that ROS1 fusion is exclusive to EGFR, KRAS, or ALK mutations and presents in a greater percentage of tumors that lack other genetic changes associated with lung cancer. [3] [4] [5] Nevertheless, at least four patients with an EGFR mutation and ROS1 fusion have been reported thus far in the world literature. 6 The patient reported herein is the fifth case, and also the first case with an EGFR exon 21 L858R point mutation and CD74-ROS1 fusion gene. Little is known about the prognostic value, clinical presentation, predictive value for different therapy regimens, and the genetic heterogeneity for two gene-positive NSCLC patients. All protocols in the present study were approved by the Human Clinical and Research Ethics Committees of the Zhejiang Corps Hospital (Jiaxing, People's Republic of China). The patient provided written informed consent.
Case report
A 50-year-old female who had never smoked was evaluated for persistent cough and shown by computed tomography (CT) scanning to have a 32 mm tumor in the right lower 
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Zhu et al lobe of the lung in November 2015 (Figure 1 ). No significant medical history was reported and no abnormalities were found on physical examination. Imaging examinations, including abdominal CT, brain magnetic resonance imaging, and bone emission computed tomography, were normal and blood laboratory testing was within normal limits, including a biochemistry and coagulation profile, and routine hematologic parameters.
The patient underwent resection of the right lower lobe and en bloc resection of the associated hilar and mediastinal lymph nodes by video-assisted thoracic surgery. The postoperative course was uneventful and the patient recovered quickly. The postoperative pathology showed that the tumor was an adenocarcinoma with sarcomatoid differentiation (Figure 2 ). Immunochemistry staining was positive for the following markers: vimentin; thyroid nuclear factor 1; P63; cytokeratin 7; and cytokeratin 5/6 (Table 1 and Figure 2 ). The tumor was stage Ib (T 2a N 0 M 0 ). Gene detection for mutations was performed on a formalin-fixed, paraffin-embedded tibia tumor specimen by next-generation sequencing and fusion genes, and c-Met 14 skipping mutation by polymerase chain reaction or fluorescence in situ hybridization on portions of the adenocarcinoma and sarcomatoid differentiation, respectively. A variant of the ROS1 translocation (Table 2 and Figure 3 ) and the EGFR exon 21 L858R point mutation were detected (Table 3 and 
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Lung cancer with a concurrent EGFR mutation
Discussion
The EGFR gene, which is located on the 12-14 region of short arm of chromosome 7, consists of 28 exons, and most mutations are located within exons 19-21 of the tyrosine kinase domain. [7] [8] [9] Point mutations in exon 21 and overlapping deletions in exon 19 account for ~85% of all mutations. 10, 11 The ROS1 rearrangement in NSCLC was discovered by Rikova et al. 12 The fusion partners include CD74-, SLC34A2-, SDC4-, EZR-, FIG-, TPM3-, LRIG3-, and KDELR2-. CD74-is the most common fusion partner in NSCLC.
3 ROS1 (chromosome 6q22) encodes a receptor tyrosine kinase that belongs to the insulin receptor family and stimulates downstream signaling via the mitogen-activated protein kinases pathway, resulting in enhanced cell growth, proliferation, and decreased apoptosis. The frequency of ROS1 rearrangements ranges from 0.9% to 1.7% in an unselected NSCLC population. 1, 13, 14 However, the frequency increases from 3.9% to 7.4% in lung adenocarcinoma patients with wild-type EGFR/KRAS/ALK. 4, 5 The EGFR tyrosine kinase inhibitors (TKIs), such as erlotinib, gefitinib, and icotinib, have been widely used as first-line treatment and have higher sensitivity compared to platinum-based chemotherapy in advanced NSCLC patients with EGFR mutations. [15] [16] [17] Deletions in exon 19 and L858R point mutations in exon 21 are the most sensitive mutations with a clear benefit from EGFR TKI treatment.
ROS1-positive patients do not benefit from treatment with EGFR TKIs. 4, 5 In contrast, patients appear to benefit from treatment with crizotinib, an orally bioavailable anaplastic lymphoma kinase (ALK) inhibitor. 18, 19 Crizotinib is currently undergoing Phase III clinical trials globally. It is anticipated that ROS1-positive NSCLC behaves in an analogous manner to EGFR mutant NSCLC, and crizotinib could represent an advance in NSCLC treatment.
Patients who have a ROS1 gene fusion and EGFR mutation are extremely rare. Previous studies have suggested 
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Zhu et al that an EGFR mutation and ROS1 gene fusion are mutually exclusive molecular events. We reviewed the literature for both EGFR and ROS1 mutations in NSCLC and found only five cases, including the present case, 6 as shown in Table 4 . Indeed, this is the first case in the Han Chinese population identified with a concurrent EGFR exon 21 L858R point mutation and a ROS1 fusion gene with a fusion partner (CD74-). Table 4 
Limitations
Our study had some limitations. First, one case of a primary lung tumor included a dominance of adenocarcinoma cells with sarcomatoid differentiation, so we do not know whether or not both mutations were related to tumor tissue heterogeneity. Second, the response to TKIs in this patient is unknown because TKIs were not used.
Conclusion
We report a rare case of lung cancer in a patient harboring both an EGFR mutation and a ROS1 fusion gene. The surgery and postoperative adjuvant chemotherapy showed a good response. For patients with this subtype, further research and experience are needed to summarize the biologic features and optimal modes of treatment, including targeted therapy in advanced lung cancer patients. 
